ESC Congress 2018

25 - 29 August 2018, Munich - Germany

Session Details

Hot Line Session 3
Mon 27 Aug 11:00 - 12:30 Other Late-Breaking Science, Mobile App - Vote and Ask a Question Munich - Main Auditorium
Chairpersons: Marco ROFFI (Geneva, Switzerland), Michael BOEHM (Homburg/Saar, Germany), Mitja LAINSCAK (Murska Sobota, Slovenia)
Learning Objectives: This is a mobile app interactive session, Audience will be invited to interact during the session by answering questions when prompted by the Mobile App Moderator and can use "Ask" to send their questions directly to the Mobile App Moderator

Access slides, videos, reports online via ESC Congress 365 Other resources

List of Presentations

Related documents
11:00 Opening question - ATTR-ACT Trial. 
11:023235ATTR-ACT Trial - Efficacy and Safety of Tafamidis in Transthyretin Amyloid CardiomyopathyClaudio RAPEZZI (Bologna, Italy)
11:123236Discussant review - ATTR-ACT.Jacob GEORGE (Rehovot, Israel)
11:173237Questions from the audience and discussion. 
11:20 Concluding question - ATTR-ACT Trial. 
11:22 Opening question - COMMANDER HF. 
11:243238COMMANDER HF - Randomized Study Comparing Rivaroxaban with Placebo in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart FailureFaiez ZANNAD (Vandoeuvre Les Nancy, France)
11:343239Discussant review - COMMANDER HF.Jean-Claude TARDIF (Montreal, Canada)
11:393240Questions from the audience and discussion. 
11:42 Concluding question - COMMANDER HF. 
11:44 Opening question - study - A randomized controlled trial evaluating the effectiveness of percutaneous mitral valve repair in secondary mitral regurgitation and reduced left ventricular ejection fractionJean-Francois OBADIA (Lyon-Bron Cedex, France)
11:563242Discussant review - WINDECKER (Bern, Switzerland)
12:013243Questions from the audience and discussion. 
12:04 Concluding question - 
12:06 Opening question - GLOBAL LEADERS TRIAL. 
12:083244GLOBAL LEADERS TRIAL - A randomized comparison of 24 month ticagrelor and 1 month aspirin versus 12 month dual antiplatelet therapy followed by aspirin monotherapyPatrick SERRUYS (Rotterdam, Netherlands)
12:183245Discussant review - GLOBAL LEADERS TRIAL.Adnan KASTRATI (Munchen, Germany)
12:233246Questions from the audience and discussion. 
12:26 Concluding question - GLOBAL LEADERS TRIAL.